PROCEPT BioRobotics (PRCT) Stock Price, News & Analysis

Company Overview

PROCEPT BioRobotics Corp. is a medical technology company focused on developing and commercializing robotic and image-guided systems for urologic procedures. The company’s primary focus is benign prostatic hyperplasia (BPH), a noncancerous enlargement of the prostate that can cause urinary symptoms.

PROCEPT’s flagship technology is Aquablation therapy, a minimally invasive, robotically controlled treatment that uses a high-velocity waterjet to remove prostate tissue. The therapy is delivered through the company’s AquaBeam Robotic System, which combines real-time imaging, surgical planning and robotic control to assist physicians during prostate procedures. PROCEPT has also developed the HYDROS Robotic System, an advanced platform designed to support Aquablation procedures.

Founded in 2007 and headquartered in Redwood Shores, California, PROCEPT BioRobotics markets its systems primarily through hospitals and urology practices. The company serves the United States and international markets, subject to applicable regulatory clearances and commercial availability. Its common stock trades on the Nasdaq under the symbol PRCT.

Key Stats

• Today's Range: $17.52 to $18.03
• 50-Day Range: $17.02 to $22.89
• 52-Week Range: $16.67 to $38.11
• Volume: 1.18 million shs
• Average Volume: 1.39 million shs
• Market Capitalization: $1.03 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $25.50
• Consensus Rating: Hold

PROCEPT BioRobotics Stock Analysis - MarketRank™

PROCEPT BioRobotics scored higher than 68% of companies evaluated by MarketBeat, and ranked 225th out of 884 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.1 / 5
• Analyst Rating: Hold

Consensus Rating

PROCEPT BioRobotics has received a consensus rating of Hold. The company's average rating score is 2.25, and is based on 1 strong buy rating, 4 buy ratings, 9 hold ratings, and 2 sell ratings.

Upside Potential

PROCEPT BioRobotics has a consensus price target of $25.50, representing about 42.5% upside from its current price of $17.90.

Amount of Analyst Coverage

PROCEPT BioRobotics has been the subject of 9 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for PROCEPT BioRobotics are expected to grow in the coming year, from ($1.67) to ($1.07) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of PROCEPT BioRobotics is -9.23, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of PROCEPT BioRobotics is -9.23, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

PROCEPT BioRobotics has a P/B Ratio of 2.73. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

13.53% of the float of PROCEPT BioRobotics has been sold short.

Short Interest Ratio / Days to Cover

PROCEPT BioRobotics has a short interest ratio ("days to cover") of 5.56.

Change versus previous month

Short interest in PROCEPT BioRobotics has recently increased by 2.64%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

PROCEPT BioRobotics does not currently pay a dividend.

Dividend Growth

PROCEPT BioRobotics does not have a long track record of dividend growth.

News and Social Media

• Score: 2.5 / 5
• News Sentiment: -0.03

News Sentiment

PROCEPT BioRobotics has a news sentiment score of -0.03. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.40 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 5 news articles for PROCEPT BioRobotics this week, compared to 9 articles on an average week.

Search Interest

7 people have searched for PRCT on MarketBeat in the last 30 days. This is an increase of 250% compared to the previous 30 days.

MarketBeat Follows

2 people have added PROCEPT BioRobotics to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days.

Company Ownership

• Score: 3.7 / 5
• Insider Trading: Acquiring Shares

Net Insider Buying

Over the last three months, insiders have purchased a net $476,464.00 in company stock, which represents 0.0465% of the company's market cap.

Insider Buying vs. Insider Selling

In the past three months, PROCEPT BioRobotics insiders have bought 2,180.51% more of their company's stock than they have sold. Specifically, they have bought $498,315.00 in company stock and sold $21,851.00 in company stock.

Percentage Held by Insiders

4.00% of the stock of PROCEPT BioRobotics is held by insiders.

Percentage Held by Institutions

89.46% of the stock of PROCEPT BioRobotics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 8/04/2026
• Today: 10/09/2026
• Next Earnings (Estimated): 11/03/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Healthcare Equipment & Supplies
• Sub-Industry: Healthcare Equipment
• Current Symbol: NASDAQ:PRCT
• CIK: 1588978
• Web: www.procept-biorobotics.com
• Phone: 650-232-7200
• Fax: N/A
• Employees: 888
• Year Founded: 2009

Price Target and Rating

• Average Price Target for PROCEPT BioRobotics: $25.50
• High Price Target: $51.00
• Low Price Target: $19.00
• Potential Upside/Downside: +42.5%
• Consensus Rating: Hold
• Rating Score (0-4): 2.31
• Research Coverage: 16 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.94)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$95.57 million
• Net Margins: -32.53%
• Pretax Margin: -32.49%
• Return on Equity: -30.62%
• Return on Assets: -22.10%

Debt

• Debt-to-Equity Ratio: 0.15
• Current Ratio: 6.55
• Quick Ratio: 5.35

Sales & Book Value

• Annual Sales: $308.05 million
• Price / Sales: 3.33
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $6.55 per share
• Price / Book: 2.73

Miscellaneous

• Outstanding Shares: 57,270,000
• Free Float: 54,983,000
• Market Cap: $1.03 billion
• Optionable: Optionable
• Beta: 0.92